search

Active clinical trials for "Head and Neck Neoplasms"

Results 121-130 of 1835

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation...

Head and Neck CancerXerostomia

The goal of this clinical research study is to evaluate the safety and tolerability of injecting certain cells that you produce in your bone marrow called mesenchymal stem cells (MSCs) into your salivary glands. Participants will have head and neck cancer that was treated with radiation therapy, and in this study will: Undergo a collection of bone marrow using a needle; Donate saliva; Undergo a salivary gland ultrasound; and, Complete questionnaires that ask about dry mouth Participants can expect to be in this study for up to 30 months.

Recruiting8 enrollment criteria

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory...

Head and Neck CancerEsophageal Cancer5 more

9 participants are expected to be enrolled for this open,single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory head and neck cancer.

Recruiting29 enrollment criteria

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

Malignant Neoplasm in the Head and NeckMetastatic Malignant Neoplasm in the Head and Neck

This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular). Embolization is a minimally invasive surgical technique performed under angiographic (imaging of blood vessels) guidance. Embolization therapy injects tiny particles into the arteries feeding tumors to cut off their blood supply which may help improve outcomes by preventing blood loss during surgery, reducing surgical times, and shrinking tumors or reducing recurrence.

Recruiting23 enrollment criteria

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated...

Head and Neck CancerHead and Neck Squamous Cell Carcinoma3 more

The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after treatment. Participation in the study should last for about 15 months while participants receive tislelizumab and chemoradiotherapy with pamiparib. Afterwards, they will return to the clinic for follow up every 4 months for 2 years, every 6 month for the next 2 years, and then once a year for the rest of their life.

Recruiting47 enrollment criteria

Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System

Thoracic CancerPancreatic Cancer Non-resectable3 more

This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent, previously irradiated thoracic cancer indicated for re- irradiation. ARM2: Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation. ARM3: Patients with unresectable pancreatic cancer. The primary objectives of the study for all arms are: 1. to describe the efficacy (local control after 3 month) and acute toxicity for patients treated with a fully-integrated CBGS and (2) to compare treatment plans between the fully-integrated CBGS and Photon therapy defined for each patient, based upon OAR sparing for comparable target coverage.

Recruiting16 enrollment criteria

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

Neck Cancer

patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab followed by (chemo)radiation.

Recruiting10 enrollment criteria

Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)

Head and Neck Cancer

This is a phase 1 study to determine the safety of a condensed preoperative radiation regimen (10, 7, or 5 fractions) for the management of head and neck squamous cell carcinoma.

Recruiting31 enrollment criteria

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally...

Squamous Cell Carcinoma of the Head and Neck

This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease.

Recruiting38 enrollment criteria

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions...

Head and Neck Cancer

To characterize the safety and tolerability of nivolumab injected intralesionally in patients with high-risk oral premalignant lesions.

Recruiting27 enrollment criteria

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers...

Squamous Cell Cancers of the Head and Neck

This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

Recruiting27 enrollment criteria
1...121314...184

Need Help? Contact our team!


We'll reach out to this number within 24 hrs